Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (311-320 of 1,058) with videos related to

Pageof 106
Sort By:
The Journal of Chemical Physics|December 5, 2012
Shock Hugoniot calculations of polymers using quantum mechanics and molecular dynamicsTanya L Chantawansri, Timothy W Sirk, Edward F C Byrd, et al.
Endocrinology|February 15, 2003
Opposing roles for the insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer cellsBeverly S Schaffer, Ming-Fong Lin, James C Byrd, et al.
Blood|October 18, 2003
Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemiaSherif S Farag, Ian W Flinn, Rama Modali, et al.
Journal of Chemical Theory and Computation|November 19, 2015
Parameterizing complex reactive force fields using multiple objective evolutionary strategies (MOES). Part 1: ReaxFF models for cyclotrimethylene trinitramine (RDX) and 1,1-diamino-2,2-dinitroethene (FOX-7)James P Larentzos, Betsy M Rice, Edward F C Byrd, et al.
Bioinformatics (Oxford, England)|January 24, 2016
MuCor: mutation aggregation and correlationKarl W Kroll, Ann-Katherin Eisfeld, Gerard Lozanski, et al.
BMC Clinical Pathology|January 18, 2006
Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinomaThaer Khoury, Dongfeng Tan, Jianmin Wang, et al.
Leukemia|February 20, 2003
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211J C Byrd, B Peterson, L Piro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistanceRajat Bannerji, Shinichi Kitada, Ian W Flinn, et al.
Nursing Management|December 1, 1990
The nurse manager resource peer: Part IIL Werkheiser, P A Negro, B J Vann, et al.
Cancer Research|September 1, 1992
Expression and characterization of mucins associated with the resistance to methotrexate of human colonic adenocarcinoma cell line HT29R Dahiya, T Lesuffleur, K S Kwak, et al.
Pageof 106

Showing results (311-320 of 1,058) with videos related to

Sort By:
Pageof 106
The Journal of Chemical Physics|December 5, 2012
Shock Hugoniot calculations of polymers using quantum mechanics and molecular dynamicsTanya L Chantawansri, Timothy W Sirk, Edward F C Byrd, et al.
Endocrinology|February 15, 2003
Opposing roles for the insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer cellsBeverly S Schaffer, Ming-Fong Lin, James C Byrd, et al.
Blood|October 18, 2003
Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemiaSherif S Farag, Ian W Flinn, Rama Modali, et al.
Journal of Chemical Theory and Computation|November 19, 2015
Parameterizing complex reactive force fields using multiple objective evolutionary strategies (MOES). Part 1: ReaxFF models for cyclotrimethylene trinitramine (RDX) and 1,1-diamino-2,2-dinitroethene (FOX-7)James P Larentzos, Betsy M Rice, Edward F C Byrd, et al.
Bioinformatics (Oxford, England)|January 24, 2016
MuCor: mutation aggregation and correlationKarl W Kroll, Ann-Katherin Eisfeld, Gerard Lozanski, et al.
BMC Clinical Pathology|January 18, 2006
Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinomaThaer Khoury, Dongfeng Tan, Jianmin Wang, et al.
Leukemia|February 20, 2003
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211J C Byrd, B Peterson, L Piro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistanceRajat Bannerji, Shinichi Kitada, Ian W Flinn, et al.
Nursing Management|December 1, 1990
The nurse manager resource peer: Part IIL Werkheiser, P A Negro, B J Vann, et al.
Cancer Research|September 1, 1992
Expression and characterization of mucins associated with the resistance to methotrexate of human colonic adenocarcinoma cell line HT29R Dahiya, T Lesuffleur, K S Kwak, et al.
Pageof 106